Camptothecins in clinical development

Expert Opinion on Investigational Drugs

Volumn 13, Issue 3, 2004, Pages 269-284

  Zunino, Franco ^a   Pratesi, Graziella ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Camptothecin; Clinical efficacy; DNA topoisomerase I

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; AFELETECAN; BAY 56 3722; BELOTECAN; BREAST CANCER RESISTANCE PROTEIN; CAMPTOTHECIN DERIVATIVE; CISPLATIN; CT 2106; CYTOTOXIC AGENT; DE 310; DIFLOMOTECAN; DNA TOPOISOMERASE; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE INHIBITOR; DRF 1042; DX 8591F; EXATECAN; FLUOROURACIL; GIMATECAN; GLIMATECAN; GLYCOPROTEIN P; IRINOTECAN; KARENITECIN; LACTONE; LURTOTECAN; PACLITAXEL; PNU 166148; POLYMER; RUBITECAN; TOPOTECAN; UNCLASSIFIED DRUG; UNINDEXED DRUG; WATER;

ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CHEMICAL MODIFICATION; CLINICAL STUDY; CLINICAL TRIAL; DIARRHEA; DOSE RESPONSE; DRUG APPROVAL; DRUG BINDING; DRUG BLOOD LEVEL; DRUG DESIGN; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG SOLUBILITY; DRUG STABILITY; DRUG TARGETING; DRUG USE; GASTROINTESTINAL TOXICITY; HEMORRHAGIC CYSTITIS; HUMAN; LIPOPHILICITY; MOLECULAR INTERACTION; NEPHROTOXICITY; NEUTROPENIA; REVIEW; STRUCTURE ACTIVITY RELATION; THROMBOCYTOPENIA;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; CHEMISTRY, PHYSICAL; DNA TOPOISOMERASES, TYPE I; DRUG DESIGN; HUMANS; POLYMERS; SOLUBILITY;

EID: 1542603100     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.13.3.269     Document Type: Review

References (113)

1. BAILLY C: Topoisomerase I poisons and suppressors as anticancer drugs. Curr. Med. Chem. (2000) 7:39-58.
2. POMMIER Y, POURQUIER P, FAN Y, STRUMBERG D: Mechanism of action of eukariotic DNA topoisomerase I and drugs targeted to the enzyme. Biochim. Biophys. Acta (1998) 1400:83-106.
3. LIU LF, DESAI SD, LI TK, MAO Y, SUN M, SIM SP: Mechanism of action of camptothecin. Ann. NY Acad. Sci. (2000) 922:1-10.
4. ZUNINO F, DALLAVALLE S, LACCABUE D, BERETTA G, MERLINI L, PRATESI G: Current status and perspectives in the development of camptothecins. Curr. Pharm. Des. (2002) 8:2505-2520.
5. WANG JC: Cellular roles of DNA tApoisomerases: a molecular perspective. Nat. Rev. Mol. Cell. Biol. (2002) 3:430-440.
6. SORET J, GABUT M, DUPON C et al.: Altered serine/arginine-rich protein phosphorylation and exonic enhancer-dependent splicing in mammalian cells lacking topoisomerase I. Cancer Res. (2003) 63:8203-8211.
7. YAO S, MURALI D, SEETHARAMULU P et al.: Topotecan lactone selectively binds to double- and single-stranded DNA in the absence of topoisomerase I. Cancer Res. (1998) 58:3782-3786.
8. MILLER SE, PILCH DS: A spectrophotometric study of the pH-dependent and DNA binding properties of topotecan. Ann. NY Acad. Sci. (2000) 922:309.
9. STAKER BL, HJERRILD K, FEESE MD, BEHNKE CA, BURGIN AB, STEWART L: The mechanism of topoisomerase I poisoning by a camptothecin analog. Proc. Natl. Acad. Sci. USA (2002) 99:15387-15392.
10. PEREGO P, CAPRANICO G, SUPINO R, ZUNINO F: Topoisomerase I gene expression and cell sensitivity to camptothecin in human cell lines of different tumor types. Anticancer Drugs (1994) 5:645-649.
11. DARZYNKIEWICZ Z, BRUNO S, DEL BINO G, TRAGANOS F: The cell cycle effects of camptothecin. Ann. NY Acad. Sci. (1996) 803:93-110.
12. POMMIER Y, GUPTA M, VALENTI M, NIEVES-NEIRA W: Cellular resistance to camtptothecins. Ann. NY Acad. Sci. (1996) 803:60-73.
13. DALLAVALLE S, MERLINI L, PENCO S, ZUNINO F: Perspective in camptothecin development. Expert Opin. Ther. Patents (2002) 12:837-844.
14. ULUKAN H, SWAAN PW: Camptothecins. A review of their chemotherapeutic potential. Drugs (2002) 62:2039-2057.
15. BURKE TG, MI Z: The structural basis of camptothecin interactions with human serum albumin: Impact on drug stability. J. Med. Chem. (1994) 37:40-46.
16. GARCIA-CARBONERO R, SOPKO JG: Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins. Clin. Cancer Res. (2002) 8:641-661.
17. PIZZOLATO JF, SALTZ LB: The camptothecins. Lancet (2003) 361:2235-2242.
18. CLARKE-PEARSON DL, VEN LE L, IVESON T et al.: Oral topotecan as single-agent second-line chemotherapy in patients with advanced ovarian cancer. J. Clin. Oncol. (2001) 19:3967-3975.
19. KRUIJTZER CMF, BEIJNEN JH, ROSING H et al.: Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918. J. Clin. Oncol. (2002) 20:2943-2950.
20. HUDES G: Boosting bioavailabilityWof topotecan: what do we gain? J. Clin. Oncol. (2002) 20:2918-2919.
21. PEREGO P, DE CESARE M, DE ISABELLA P et al.: A novel 7-modified camptothecin analog overcomes breast cancer resistance protein-associated resistance in a mitoxantrone-selected colon carcinoma cell line. Cancer Res. (2001) 61:6034-6037.
22. SPARREBOOM A, DANESI R, ANDO Y, CHAN J, FIGG WD: Pharmacogenomics of ABC transporters and its role in cancer chemotherapy. Drug Resist. Update (2003) 6:71-84.
23. ALLEN JD, SCHINKEL AH: Multidrug resistance and pharmacological protection mediated by the breast cancer resistance protein (BCRP/ABCG2). Mol. Cancer Ther. (2002) 1:427-434.
24. PIZZOLATO JF, SALTZ LB: Irinotecan (Campto) in the treatment of pancreatic cancer. Expert Rev. Anticancer Ther. (2003) 3:587-593.
25. MORTON CL, WADKINS RM, DANKS MK, POTTER PM: The anticancer prodrug CPT-11 is a potent inhibitor of acetylcholinesterase but is rapidly catalyzed to SN-38 by butyrylcholinesterase. Cancer Res. (1999) 59:1458-1463.
26. GUPTA E, LESTINGI TM, MICK R, RAMIREZ J, VOKES EE, RATAIN MJ: Metabolic fate or irinotecan in humans: Correlations of glucuronidation with diarrhea. Cancer Res. (1994) 54:3723-3725.
27. XIE R, MATHIJSSEN RHJ, SPARREBOOM A, VERWEIJ J, KARLSSON MO: Clinical pharmacokinetics of irinotecan and its metabolites in relation with diarrhea. Clin. Pharmacol. Ther. (2002) 72:265-275.
28. DALLAVALLE S, FERRARI A, BIASOTTI B et al.: Novel 7-oxyiminomethyl derivatives of camptothecin with potent in vitro and in vivo antitumor activity. J. Med. Chem. (2001) 44:3264-3274.
29. CUNNINGHAM D, MAROUN J, VANHOEFER U, VAN CUTSEM E: Optimizing the use of irinotecan in colorectal cancer. Oncologist (2001) 6:17-23.
30. AISNER J, MUSANTI R, BEERS S, SMITH S, LOCSIN S, RUBIN EH: Sequencing topotecan and etoposide plus cisplatin to overcome topoisomerase I and II resistance: A pharmacodynamically based Phase I trial. Clin. Cancer Res. (2003) 9:2504-2509.
31. LICITRA EJ, VYAS V, NELSON K et al.: Phase I evaluation of sequential topoisomerase targeting with irinotecan/ cisplatin followed by etoposide in patients with advanced malignancy. Clin. Cancer Res. (2003) 9:1673-1679.
32. ZEGHARI-SQUALLY N, RAYMOND E, CVITKOVIC E, GOLDWASSER F: Cellular pharmacology of the combination of the DNA topoisomerase I inhibitor SN-38 and the diaminocyclohexane platinum derivative oxaliplatin. Clin. Cancer Res. (1999) 5:1189-1196.
33. BOIGE V, RAYMOND E, FAIVRE S et al.: Phase I and pharmacokinetic study of the camptothecin analog DX-8951f administered as a 30-minute infusion every 3 weeks in patients with advanced cancer. J. Clin. Oncol. (2000) 18:3986-3992.
34. ROYCE ME, HOFF PM, DUMAS P et al.: Phase I and pharmacokinetic study of exatecan mesylate (DX-8951f): A novel camptothecin analog. J. Clin. Oncol. (2001) 19:1493-1500.
35. GILLES FJ, CORTES JE, THOMAS DA et al.: Phase I and pharmacokinetic study of DX-8951f (exatecan mesylate), a hexacyclic camptothecin, on a daily-times-five schedule in patients with advanced leukemia. Clin. Cancer Res. (2002) 8:2134-2141.
36. GARRISON MA, HAMMOND LA, GEYER CE et al.: A Phase I and pharmacokinetic study of exatecan mesylate administered as a protracted 21-day infusion in patients with advanced solid malignancies. Clin. Cancer Res. (2003) 9:2527-2537.
37. ESTEVA FJ, RIVERA E, CRISTOFANILLI M et al.: A Phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for 5 days every 3 weeks to patients with metastatic breast carcinoma. Cancer (2003) 98:900-907.
38. GAMUCCI T, PARIDAENS R, HEINRICH B et al.: Activity and toxicity of GI147211 in breast, colorectal and non-small-cell lung cancer patients: An EORTC-ECSG Phase II clinical study. Ann. Oncol. (2000) 11:793-797.
39. LOOS WJ, KEHRER D, BROUWER E et al.: Liposomal lurtotecan (NX211): Determination of total drug levels in human plasma and urine by reversed-phase high-performance liquid chromatography. J. Chromatogr. B. Biomed. Appl. (2000) 738:155-163.
40. KEHRER DFS, BOS AM, VERWEIJ J et al.: Phase I and pharmacologic study of liposomal lurtotecan, NX211: Urinary excretion predicts hematologic toxicity. J. Clin. Oncol. (2002) 20:1222-1231.
41. CALVERT AH, GRIMSHAW R, POOLE C et al.: Randomized Phase II trial of two intravenous schedules of the liposomal topoisomerase I inhibitor, NX211, in women with relapsed epithelial ovarian cancer (OVCA): An NCIC CTG study. Proc. Am. Soc. Clin. Oncol. (2002) 21(Abstract 830).
42. LEE JH, LEE JM, LIM KH et al.: Preclinical and Phase I clinical studies with CKD-602, a novel camptothecin derivative. Ann. NY Acad. Sci. (2000) 922:324-325.
43. SONG Y, SEO S-S, BANG Y-J et al.: Phase II evaluation of ckd-602, a camptothecin analog, administered on a 5-day schedule in patients with recurrent or refractory ovarian cancer. Proc. Am. Soc. Clin. Oncol. (2003) 22(Abstract 1877).
44. LERCHEN HG, BAUMGARTEN J, VON DEM BRUCH K et al.: Design and optimization of 20-O-linked camptothecin glycocomjugates as anticancer agents. J. Med. Chem. (2001) 44:4186-4195.
45. MROSS K, SAUER U, HARING B et al.: A Phase I dose scalation pharmacokinetic (PK) study of BAY 38-3441 administered as a short infusion once every three weeks. Proc. Am. Soc. Clin. Oncol. (2002) 21(Abstract 396).
46. SIU LL, BATIST G, BANGASH N et al.: A Phase I study of BAY 38-3441 given as a short infusion daily for five days every 3 weeks: A National Cancer Institute of Canada Clinical Trials Group study. Proc. Am. Soc. Clin. Oncol. (2002) 21(Abstract 395).
47. CHATTERJEE A, DIGUMARTI R, MAMIDI RN et al.: DRF-1042, a novel orally active camptothecin (CPT) analog: Safety, pharmacokinetic (PK) and pharmacodynamic evaluation in a Phase I dose escalation study. Proc. Am. Soc. Clin. Oncol. (2002) 21(Abstract 384).
48. VERSCHRAEGEN CF, NATELSON EA, GIOVANELLA BC et al.: A Phase I clinical and pharmacological study of oral 9-nitrocamptothecin, a novel water-insoluble topoisomerase I inhibitor. Anticancer Drugs (1998) 9:36-44.
49. STEHLIN JS, GIOVANELLA BC, NATELSON EA et al.: A study of 9-nitrocamptothecin (RFS-2000) in patients with advanced pancreatic cancer. Int. J. Oncol. (1999) 14:821-831.
50. MICHAELSON MD, RYAN DP, FUCHS CS et al.: A Phase I study of 9-nitrocamptothecin given concurrently with capecitabine in patients with refractory, metastatic solid tumors. Cancer (2003) 97:148-154.
51. RAJENDRA R, GOUNDER MK, SALEEM A et al.: Differential effects of the breast cancer resistance protein on the cellular accumulation and cytotoxicity of 9-aminocamptothecin and 9-nitrocamptothecin. Cancer Res. (2003) 63:3228-3233.
52. XIONG HQ, TRAN HT, MADDEN TL, NEWMAN RA, ABRUZZESE JL: Phase I and pharmacological study of oral 9-aminocamptothecin colloidal dispersion (NSC 603071) in patients with advanced solid tumors. Clin. Cancer Res. (2003) 9:2066-2071.
53. LEGUIZAMO J, QUINN M, TAKIMOTO CH et al.: A Phase I study of 9-aminocamptothecin as a colloidal dispersion formulation given as a fortnightly 72-h infusion. Cancer Chemother. Pharmacol. (2003) 52:333-338.
54. BOM D, CURRAN DP, KRUSZEWSKI S, ZIMMER SG, STRODE JT, KOHLHAGEN G: The novel silatecan 7-tert-butyldimethylsilyl-10-hydroxycamptothecin displays high lipophilicity, improved human blood stability, and potent anticancer activity. J. Med. Chem. (2000) 43:3970-3980.
55. POLLACK IF, ERFF M, BOM D, BURKET G, STRODE JT, CURRAN DP: Potent topoisomerase I inhibition by novel silatecans eliminates glioma proliferation in vitro and in vivo. Cancer Res. (1999) 59:4898-4905.
56. VAN HATTUM AH, PINEDO HM, SCHLUPER HMM, HAUSHEER FH, BOVEN E: New highly lipophilic camptothecin BNP1350 is an effective drug in experimental human cancer. Int. J. Cancer (2000) 88:260-266.
57. VAN HATTUM AH, SCHLUPER HMM, HAUSHEER FH, PINEDO HM, BOVEN E: Novel camptothecin derivative BNP1350 in experimental human ovarian cancer: Determination of efficacy and possible mechanisms of resistance. Int. J. Cancer (2002) 100:22-29.
58. THOMPSON P, BERG S, GURURANGAN S et al.: A Phase I study of karenitecin in children. Proc. Am. Ass. Cancer Res. (2002) (Abstract 2748).
59. DAUD A, BALAR B, VALKOV N et al.: Phase II trial of karenitecin, a novel topoisomerase I inhibitor in metastatic melanoma: clinical and translational study. Proc. Am. Soc. Clin. Oncol. (2003) 22(Abstract 2871).
60. HERNDON JE, MILLER AA, ZHANG C et al.: Phase II trial of karenitecin in patients with refractory non-small cell lung cancer (NSCLC): CALGB 30004. Proc. Am. Soc. Clin. Oncol. (2003) 22(Abstract 2706).
61. BAILLY C: HomPcamptothecins: potent topoisomerase I inhibitors and promising anticancer drugs. Crit. Rev. in Oncol. Hematol. (2003) 45:91-108.
62. SCOTT LC, SOEPENBERG O, TWELVES C et al.: A pharmacological comparison of Phase I studies of diflomotecan (BN80915) administered orally and intravenously daily for 5 days every 3 weeks in patients with solid tumors. Proc. Am. Soc. Clin. Oncol. (2002) 21(Abstract 534).
63. GELDERBLOM H, SALAZAR R, VERWEIJ J et al.: Phase I pharmacological and bioavailability study of oral diflomotecan (BN80915), a novel E-Ring-modified camptothecin analogue in adults with solid tumors. Clin. Cancer Res. (2003) 9:4101-4107.
64. DALLAVALLE S, DELSOLDATO T, FERRARI A et al.: Novel 7-substituted camptothecins with potent antitumor activity. J. Med. Chem. (2000) 43:3963-3969.
65. DE CESARE M, PRATESI G, PEREGO P et al.: Potent antitumor activity and improved pharmacological profile of ST1481, a novel 7-substituted camptothecin. Cancer Res. (2001) 61:7189-7195.
66. PRATESI G, DE CESARE M, CARENINI N et al.: Pattern of antitumor activity of a novel camptothecin, ST1481, in a large panel of human tumor xenografts. Clin. Cancer Res. (2002) 8:3904-3909.
67. ZUCCHETTI M, PACE S, FRAPOLLI R et al.: Clinical pharmacokinetic profile of gimatecan (ST1481), a new derivative. Proc. Am. Soc. Clin. Oncol. (2002) 21(Abstract 476).
68. CROCE A, BOTTIROLI G, SUPINO R et al.: Subcellular localization of the camptothecin analogues, topotecan and gimatecan. Biochem. Pharmacol. (2004) (In press).
69. PETRANGOLINI G, PRATESI G, DE CESARE M et al.: Antiangiogenic effects of the novel camptothecin ST1481 (gimatecan) in human tumor xenografts. Mol. Cancer Res. (2003) 1:863-870.
70. GIANNI L, HESS D, BASELGA J et al.: A Phase I study of the oral camptothecin gimatecan with a design of cencerted dose escalation in three schedules of different dosing-duration. Proc. Am. Soc. Clin. Oncol. (2003) 22(Abstract 554).
71. ALDERSON L, SUPKO J, MAESTRI X et al. Phase I/II trial of gimatecan in patients with recurrent malignant glioma. Proc. Am. Soc. Clin. Oncol. (2003) 22:(Abstract 416).
72. ZHU AX, READY NE, CLARK JW et al.: Phase I trial of gimatecan given orally once a week for 3 or 4 weeks in patients with advanced solid tumors. Proc. Am. Soc. Clin. Oncol. (2003) 22(Abstract 557).
73. SEYMOUR LW: Passive tumor targeting of soluble macromolecules drug conjugates. Crit. Rev. Ther. Drug Carrier Sys. (1992) 9:135-187.
74. GREENWALD RB, CHOE YH, MCGUIRE J, CONOVER CD: Effective drug delivery by PEGylated drug conjugates. Adv. Drug Deliv. Rev. (2003) 55:217-250.
75. ZHAO H, LEE C, SAI P et al.: 20-O-acylcamptothecin derivatives: Evidence for lactone stabilization. J. Org. Chem. (2000) 65:4601-4606.
76. ROWINSKY EK, RIZZO J, OCHOA L et al.: A Phase I and pharmacokinetic study of pegylated camptothecin as a 1-hour infusion every 3 weeks in patients with advanced solid malignancies. J. Clin. Oncol. (2003) 21:148-157.
77. SCHOEMAKER NE, VAN KESTEREN C, ROSING H et al.: A Phase I and pharmacokinetic study of MAG-CPT, a water-soluble polymer conjugate of camptothecin. Br. J. Cancer (2002) 87:608-614.
78. SARAPA N, BRITTO MR, SPEED W et al.: Assessment of normal and tumor tissue uptake of MAG-CPT, a polymer-bound prodrug of camptothecin, in patients undergoing elective surgery for colorectal carcinoma. Cancer Chemother. Pharmacol. (2003) 52:424-430.
79. INOUE K, KUMAZAWA E, KUGA H, SUSAKI H, MASUBUCHI N, KAJIMURA T: CM-dextran-polyalcohol-camptothecin conjugate: DE-310 with a novel carrier system and its preclinical data. Adv. Exp. Med. Biol. (2003) 519:145-153.
80. TAKIMOTO CHM, FORERO L, SCHWARTZ GH et al.: A Phase I and pharmacokinetic study of DE-310 administered as a 3 hour infusion every 4 weeks (wks) to patients (pts) with advanced solid tumors or lymphomas. Proc. Am. Soc. Clin. Oncol. (2003) 22(Abstract 522).
81. SOEPENBERG O, DE JONGE M, SPARREBOOM A et al.: Phase I and PK study of DE-310 (D) given once every 2 or 6 wks (w) in pts with solid tumors. Proc. Am. Soc. Clin. Oncol. (2003) 22(Abstract 523).
82. BHATT R, DE VRIES P, TULINSKY J et al.: Synthesis and in vivo antitumor activity of poly(L-glutamic acid) conjugates of 20S-camptothecin. J. Med. Chem. (2003) 46:190-193.
83. SINGER JW, BHATT R, TULINSKY J et al.: Water-soluble poly-(L-glutamic acid)-gly-camptothecin conjugates enhance camptothecin stability and efficacy in vivo. J. Control Release (2001) 74:243-247.
84. SINGER JW, DE VRIES P, BHATT R et al.: Conjugation of camptothecins to poly-(L-glutamic acid). Ann. NY Acad. Sci. (2000) 922:136-150.
85. KINGSBURY WD, BOEHM JC, JAKAS DR et al.: Synthesis of water-soluble (aminoalkyl) camptothecin analogues: Inhibition of topoisomerase I and antitumor activity. J. Med. Chem. (1991) 34:98-107.
86. KUNIMOTO T, NITTA K, TANAKA T et al.: Antitumor activity of 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy-camptothecin, a novel water-soluble derivative of camptothecin, against murine tumors. Cancer Res. (1987) 47:5944-5947.
87. GIOVANELLA BC, HINZ HR, KOZIELSIK AJ, STEHLIN JS Jr, SILBER R, POTMESIL M: Complete growth inhibition of human cancer xenografts in nude mice by treatment with 20-(S)-camptothecin. Cancer Res. (1991) 51:3052-3055.
88. MITSUI I, KUMAZAWA E, HIROTA Y et al.: A new water-soluble camptothecin derivative, DX-8951f, exhibits potent antitumor activity against human tumors in vitro and in vivo. Jpn. J. Cancer Res. (1995) 86:776-782.
89. UPRETI VV, MAMIDI RNVS, KATNENI K, SRINIVAS NR: Quantitative determination of DRF-1042 in human plasma by HPLC: Validation and application in clinical pharmacokinetics. Biomed. Chromatog. (2003) 17:385-390.
90. COLBERN GT, DYKES DJ, ENGBERS C et al.: Encapsulation of the topoisomerase I inhibitor GL147211C in pegylated (STEALTH) liposomes: pharmacokinetics and antitumor activity in HT29 colon tumor xenografts. Clin. Cancer Res. (1998) 4:3077-3082.
91. HAUSHEER F, HARIDAS K, ZHAO M et al.: Karenitecins (part II): a novel class of orally active highly lipophilic topoisomerase I inhibitors. Proc. Am. Ass. Cancer Res. (1998) 39:(Abstract 2862).
92. LAVERGNE O, LESUEUR-GINOT L, PLA RODAS F et al.: Homocamptothecins: Synthesis and antitumor activity of novel E-ring-modified camptothecin analogues. J. Med. Chem. (1998) 41:5410-5419.
93. BATIST G, SIUAL, MACLEAN M et al.: NCIC CTG Ind. 134: a Phase I study of a novel glycoconjugated camptothecin (BAY 38-3441) given as a short infusion daily for five days every 3 weeks. Proc. Am. Ass. Cancer Res. (2001) 42:(Abstract 2896).
94. CAIOLFA VR, ZAMAI M, FIORINO A et al.: Polymer-bound camptothecin: Initial biodistribution and antitumor activity studies. J. Control Release (2000) 65:105-119.
95. MINKO T, PARANJPE PV, LALLOO BQA et al.: Enhancing the anticancer efficacy of camptothecin using biotinylated poly(ethyleneglycol) conjugates in sensitivie and multidrug-resistant human ovarian carcinoma cells. Cancer Chemother. Pharmacol. (2002) 50:143-150.
96. SPEYER J, HOCHSTER H, WADLER S et al.: Effective first line therapy of ovarian cancer (OC) with cisplatin and prolonged topotecan infusion-a NY-GOG/ECOG Study. Proc. Am. Soc. Clin. Oncol. (2000) 19:380a (Abstract).
97. BOLIS G, SCARFONE G, SCIATTA C, PARAZZIN F: A Phase II study of topotecan (T), carboplatin (C) and paclitaxel (P) as front line treatment in suboptimal advanced epithelial ovarian cancer (AEOC). Proc. Am. Soc. Clin. Oncol. (2000) 19:390a (Abstract).
98. LYNCH T, HERNDON J, LYSS A et al.: Paclitaxel (P) + topotecan (T) + GCSF for previously untreated extensive small cell lung cancer (E-SCLC): Preliminary analysis of cancer and leukaemia group B (CALGB) 9430. Proc. Am. Soc. Clin. Oncol. (2000) 19:491a (Abstract).
99. GRAY J, HAINSWORTH J, BURRIS H et al.: Paclitaxel, carboplatin, and topotecan in the treatment of small cell lung cancer: A Phase II trial of the Minnie Pearl Cancer Research Network. Proc. Am. Soc. Clin. Oncol. (2000) 19:494a (Abstract).
100. ARDIZZONI A, MANEGOLD C, DEBRUYNE C et al.: European organization for research and treatment of cancer (EORTC) 08957 Phase II study of topotecan in combination with cisplatin as second-line treatment of refractory and sensitive small cell lung cancer. Clin. Cancer Res. (2003) 9:143-150.
101. MOK TS, WONG H, ZEE B et al.: A Phase I-II study of sequential administration of topotecan and oral etoposide (topoisomerase I and II inhibitors) in the treatment of patients with small cell lung carcinoma. Cancer (2002) 95:1511-1519.
102. RINALDI DA, LORMAND NA, BRIERRE JE et al.: A Phase II trial of topotecan and gemcitabine in patients with previously treated, advanced nonsmall cell lung carcinoma. Cancer (2002) 95:1274-1278.
103. BERAN M, ESTEY E, O'BRIEN S et al.: Topotecan and cytarabine is an active combination regimen in myelodysplastic syndromes and chronic myelomonocytic leukaemia. J. Clin. Oncol. (1999) 17:2819-2830.
104. DOUILLARD JT, CUNNINGHAM D, ROTH AD et al.: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial. Lancet (2000) 355:1041-1047.
105. SALTZ LB, COX JV, BLANKE C et al.: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. (2000) 343:905-914.
106. MASUDA N, FUKUOKA M, NEGORO S et al.: Randomized trial comparing cisplatin and irinotecan versus cisplatin and vindesine versus irinotecan alone in advanced non-small cell lung cancer, a multicenter Phase III study. Proc. Am. Soc. Clin. Oncol. (1999) 18:459a (Abstract).
107. NIHO S, NAGAO K, NISHIWAKI Y et al.: Randomized multicenter Phase III trial of irinotecan (CPT-11) and cisplatin (CDDP) versus CDDP and vindesine (VDS) in patients with advanced non-small cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Oncol. (1999) 18:1897 (Abstract).
108. NODA K, NISHIWAKA Y, KAWAHARA M. et al.: Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N. Engl. J. Med. (2002) 346:85-91.
109. BOKU N, OHTSU A, SHIMADA Y et al.: Phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer. J. Clin. Oncol. (1999) 17:319-323.
110. ASSERSOHN L, BROWN G, CUNNINGHAM D et al.: Phase II study of irinotecan and 5-fluorouracil/leucovorin in patients with primary refractory or relapsed advanced oesophageal and gastric carcinoma. Ann. Oncol. (2004) 15:64-69.
111. ILSON DH, SALTZ L, ENZINGER P et al.: Phase II trial of weekly irinotecan plus cisplatin in advanced esophageal cancer. J. Clin. Oncol. (1999) 17:3270-3275.
112. ROCHA LIMA CM, SAVARESE D, BRUCKNER H et al.: Irinotecan plus gemcitabine induces both radiographic and CA 19-9 tumor marker responses in patients with previously untreated advanced pancreatic cancer. J. Clin. Oncol. (2002) 20:1182-1191.
113. STATHOPOULOS GP, RIGATOS SK, DIMOPOULOS MA et al.: Treatment of pancreatic cancer with a combination of irinotecan (CPT-11) and gemcitabine: A multicenter Phase II study by the Greek Cooperative Groups for Pancreatic Cancer. Ann. Oncol. (2003) 14:388-394.